Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes
Open accessThe DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
OBJECTIVE: To assess the effects of exenatide on body weight and glucose tolerance in nondiabetic obese subjects with normal or impaired glucose tolerance (IGT) or impaired fasting glucose (IFG). RESEARCH DESIGN AND METHODS: Obese subjects (n = 152; age 46 ± 12 years, female 82%, weight 108.6 ± 23.0 kg, BMI 39.6 ± 7.0 kg/m2, IGT or IFG 25%) were randomized to receive exenatide (n = 73) or placebo (n = 79), along with lifestyle intervention, for 24 weeks. RESULTS: Exenatide-treated subjects lost 5.1 ± 0.5 kg from baseline versus 1.6 ± 0.5 kg with placebo (exenatide − placebo, P < 0.001). Placebo-subtracted difference in percent weight reduction was −3.3 ± 0.5% (P < 0.001). Both groups reduced their daily calorie intake (exenatide, −449 cal; placebo, −387 cal). IGT or IFG normalized at end point in 77 and 56% of exenatide and placebo subjects, respectively. CONCLUSIONS: Exenatide plus lifestyle modification decreased caloric intake and resulted in weight loss in nondiabetic obesity with improved glucose tolerance in subjects with IGT and IFG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Exenatide and liraglutide were both found to produce sustained weight loss among obese subjects and were associated with increased reversion from prediabetes to normoglycaemia over 1–2 years of follow-up. The most frequent side effects were nausea and vomiting in these studies.105–107”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [106]
Experimental — accuracy not yet measuredIn the citing paper
“At present, the studies of EX on non-diabetic obesity mainly include 152 cases of simple obesity (weight loss of 5.1 kg) (54), 60 cases of polycystic ovary syndrome (weight loss of 3.2-6.0 kg) (55), and 10 cases of metabolic syndrome (weight loss of 3.7 kg) (56), among which the most common adverse reaction is still vomiting.”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [54]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 16 · Cited by 229
Research works printed but not linked: 1
- Lindström, 2003, Lifestyle intervention and 3-year results on diet and physical activity, Diabetes Care, 26, 3230
Metadata
- Authors
- Rosenstock, J., Klaff, L. J., Schwartz, S., Northrup, J., Holcombe, J. H., Wilhelm, K., & Trautmann, M.
- Affiliations
- Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas;
- Rainier Clinical Research Center (US)
- Diabetes & Glandular Disease Clinic (US)
- Eli Lilly (United States) (US)
- Amylin Pharmaceuticals, San Diego, California.
- Corresponding author
- Rosenstock, Julio
- ORCID
- Rosenstock, Julio
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2010-03-23
- Volume
- 33
- Issue
- 6
- Pages
- 1173-1175
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2875418
- OpenAlex
- W2107037013
- Cited by
- 229
- References
- 16
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 10 · 2023: 11 · 2022: 8 · 2021: 6 · 2020: 6 · 2019: 8 · 2018: 8 · 2017: 16 · 2016: 15 · 2015: 20 · 2014: 19 · 2013: 28 · 2012: 25
- FWCI
- 19.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Amylin Pharmaceuticals
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- MannKind Corporation
- Daiichi-Sankyo
- Novo Nordisk
- Johnson and Johnson
- Fogarty International Center
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- exenatide, GLP-1 receptor agonists, obesity, impaired glucose tolerance, impaired fasting glucose, prediabetes, lifestyle modification, weight loss, glucose tolerance, energy intake
- MeSH terms
- Exenatide, Adult, Blood Glucose, Body Weight, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Motor Activity, Obesity, Peptides, Prediabetic State, Venoms, Glucose Intolerance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes. https://app.cochat.ai/papers/10.2337/dc09-1203
- The paper
- Rosenstock, J., Klaff, L. J., Schwartz, S., Northrup, J., Holcombe, J. H., Wilhelm, K., & Trautmann, M. (2010). Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes. Diabetes Care. https://doi.org/10.2337/dc09-1203
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.